A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Latest Information Update: 05 Nov 2024
At a glance
- Drugs MT-8421 (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Cervical cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Molecular Templates
- 01 Nov 2024 Status changed from active, no longer recruiting to discontinued as per sponsor.
- 21 Oct 2024 Planned End Date changed from 1 Oct 2026 to 31 Oct 2024.
- 21 Oct 2024 Planned primary completion date changed from 1 Jul 2026 to 31 Oct 2024.